Esophageal Squamous Cell Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Cancer (195)

Esophageal Adenocarcinoma (39)

Esophageal Cancer (195)

Esophageal Adenocarcinoma (39)

›

No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 2 days (New A1) sugemalimab Sensitive : A1 CStone Pharma Press Release - 2d	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 2 days sugemalimab Sensitive : A1 CStone Pharma Press Release - 2 days - (New A1)
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: A1 - Approval Korea Biomedical Review - 2 weeks (New A1) tislelizumab Sensitive : A1 Korea Biomedical Review - 2wk	tislelizumab Sensitive: A1 - Approval Korea Biomedical Review - 2 weeks tislelizumab Sensitive : A1 Korea Biomedical Review - 2 weeks - (New A1)
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
HER-2 negative	Esophageal Squamous Cell Carcinoma	HER-2 negative	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
RET fusion	Esophageal Squamous Cell Carcinoma	RET fusion	Esophageal Squamous Cell Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
BRAF V600E	Esophageal Squamous Cell Carcinoma	BRAF V600E	Esophageal Squamous Cell Carcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
NTRK3 fusion	Esophageal Squamous Cell Carcinoma	NTRK3 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Esophageal Squamous Cell Carcinoma	NTRK2 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Esophageal Squamous Cell Carcinoma	NTRK1 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
EGFR mutation	Esophageal Squamous Cell Carcinoma	EGFR mutation	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1
HER-2 positive	Esophageal Squamous Cell Carcinoma	HER-2 positive	Esophageal Squamous Cell Carcinoma	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2
MUC1 expression + EGFR expression	Esophageal Squamous Cell Carcinoma	MUC1 expression + EGFR expression	Esophageal Squamous Cell Carcinoma	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2	M1231 Sensitive: C2 – Inclusion Criteria M1231 Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab + BGB-A1217 Sensitive : C2	tislelizumab + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab + BGB-A1217 Sensitive : C2
NRG1 overexpression	Esophageal Squamous Cell Carcinoma	NRG1 overexpression	Esophageal Squamous Cell Carcinoma	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3
NDRG1 overexpression	Esophageal Squamous Cell Carcinoma	NDRG1 overexpression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3
SGK1 overexpression	Esophageal Squamous Cell Carcinoma	SGK1 overexpression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3
AFAP1-AS1 overexpression	Esophageal Squamous Cell Carcinoma	AFAP1-AS1 overexpression	Esophageal Squamous Cell Carcinoma	FP Resistant: C3 – Early Trials FP Resistant : C3	FP Resistant: C3 – Early Trials FP Resistant : C3
TLR signature	Esophageal Squamous Cell Carcinoma	TLR signature	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3
DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKK1 overexpression	Esophageal Squamous Cell Carcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3

Esophageal Squamous Cell Carcinoma

Associations(90)

Associations
(90)